MedTrace Logo

Two Bupivacaine Concentrations for Erector Spinae Plane Block in Percutaneous Nephrolithotomy

NCT07653230 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2026-06-17

No results posted yet for this study

Summary

People who undergo percutaneous nephrolithotomy (PNL), a procedure used to remove kidney stones, often experience pain after surgery. An ultrasound-guided erector spinae plane block (ESPB) is commonly used to help reduce this pain.

This study compares two different concentrations of bupivacaine, a local anesthetic medication, used during ESPB. Participants undergoing PNL will receive either 0.25% or 0.375% bupivacaine as part of their pain management.

Researchers will compare pain scores, the need for additional pain medication, and changes in blood markers related to inflammation after surgery. The aim of the study is to determine whether one concentration provides better pain control or influences the inflammatory response differently after PNL.

Conditions

  • Percutaneous Nephrolithotomy (PNL)
  • Nephrolithiasis

Interventions

PROCEDURE

Erector spinae plane block (ESPB)

Ultrasound-guided thoracic erector spinae plane block was performed at the T10 vertebral level before surgery by an experienced anesthesiologist. A total volume of 20 mL bupivacaine was administered. Participants received either 0.25% or 0.375% bupivacaine according to the study cohort. The block was used as part of a multimodal analgesia protocol for postoperative pain management following percutaneous nephrolithotomy.

Sponsors & Collaborators

  • Ankara Education and Research Hospital

    lead OTHER_GOV

Principal Investigators

  • suna akın takmaz, proffessor doctor · University of Health Sciences, Ankara Training and Research Hospital, Ankara, Türkiye

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-01
Primary Completion
2025-03-18
Completion
2025-03-19

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07653230 on ClinicalTrials.gov